BOSTON, Nov. 21, 2011 /PRNewswire/ -- Perceptive Informatics, a leading eClinical solutions provider and a subsidiary of PAREXEL International Corporation (NASDAQ: PRXL), today announced results of a global survey conducted during its webinar entitled "Medical Imaging Web Reporting: Helping Sponsors Simplify Central Imaging Study Management through Metrics." Perceptive polled biopharmaceutical industry professionals across a broad range of outsourcing, clinical operations, and technical functions about the value of accessing medical imaging metrics to provide greater visibility into clinical trials and to achieve major study milestones.
The survey results revealed that over half (54%) of respondents review medical imaging related study metrics on a regular basis. Of those respondents, 81% use medical imaging metrics as actionable data to inform progress toward the achievement of study milestones. Key performance indicators used by the respondents include the status of site qualification for imaging-based clinical trials, as well as progress of medical image submissions, query responses, and radiology reviews.
"Industry-standard performance metrics for imaging core labs have become an important element of effective study management. Centralized access to medical imaging metrics for multiple trials and cross-study program monitoring is especially critical for comprehensive analysis," said Kenneth G. Faulkner, Ph.D., Vice President, Medical Imaging, Perceptive Informatics. "Perceptive Informatics is focused on providing sophisticated reporting capabilities to help our clients optimize strategic decision-making about the performance of their imaging-based clinical trials."
The medical imaging reporting solution from Perceptive Informatics is designed to present medical imaging data for improved analysis and decision-making. The imaging dashboard, which provides key performance indicators, is enabled by a comprehensive suite of reports. The solution is aligned with industry-standard metrics for imaging core labs, as defined by the Metrics Champion Consortium (MCC), allowing trial sponsors to track progress against MCC criteria.
For more information about medical imaging capabilities from Perceptive Informatics visit: www.perceptive.com/imaging.
About Perceptive InformaticsPerceptive Informatics, a leading eClinical solutions provider and subsidiary of PAREXEL, is focused on helping customers to accelerate the product development process through innovation. Perceptive enables customers to maximize the benefits of clinical trial technologies by providing flexible software-as-a-service (SaaS) applications and leading technology services. The Perceptive Informatics eClinical Suite is built on extensive medical and clinical expertise, as well as a deep understanding of the regulatory environment. The suite includes Randomization and Trial Supply Management (RTSM) technologies, Medical Imaging, Clinical Trial Management Systems (CTMS), Electronic Data Capture (EDC), and Electronic Patient-Reported Outcomes (ePRO). The Perceptive Informatics eClinical Suite blurs the boundaries among systems that traditionally have been used in isolation, resulting in simplified workflow, improved efficiency and enhanced productivity. For more information about the integrated solutions in the Perceptive Informatics eClinical Suite visit www.perceptive.com.
About PAREXEL InternationalPAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 67 locations throughout 52 countries around the world, and has approximately 10,850 employees. For more information about PAREXEL International visit www.PAREXEL.com.
This release contains "forward-looking" statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand.
For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "will," "would," "could," "should," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings, including the anticipated additional restructuring charges of approximately $4 million in the second quarter of Fiscal Year 2012; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks.
Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2011 as filed with the SEC on November 9, 2011, which "Risk Factors" discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged
Contacts: Jennifer Baird, Senior Director of Public Relations
Kim Leadley/Gene CarozzaPAREXEL International
PAN CommunicationsTel: +781-434-4409
Tel: + 617-502-4300Email: Jennifer.Baird@PAREXEL.com
|SOURCE PAREXEL International Corporation|
Copyright©2010 PR Newswire.
All rights reserved